FDA Recalls Granisetron HCl Injectable Drug Due to Manufacturing Compliance Failure
Akorn, Inc. recalls all lots of Granisetron HCl Injection nationwide because the manufacturer ceased operations and cannot complete required stability studies, leaving the drug's shelf-life unverified.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall due to CGMP deviations and incomplete stability testing. The manufacturer ceased operations and cannot verify the drug's shelf-life and potency. No illnesses or adverse events reported, classifying this as a precautionary quality-control recall with theoretical rather than demonstrated hazard.
Plain-English summary
Akorn, Inc. has recalled all lots of Granisetron HCl Injection, USP, 1 mg/mL, for intravenous use nationwide in the USA and Puerto Rico. The recall applies to both 1 mL and 4 mL vial presentations under all National Drug Codes (NDCs).
The FDA classified this as a Class II recall due to Current Good Manufacturing Practice (CGMP) deviations. Akorn ceased operations and can no longer conduct the ongoing stability studies required to demonstrate that the drug remains safe and effective throughout its shelf life. Without completed stability testing, the safety and potency of the product cannot be verified over time.
No illnesses or injuries have been reported. Healthcare providers should immediately stop distributing this product and quarantine existing inventory. Patients currently using this medication should consult their healthcare provider about alternative treatments. Wholesalers, hospitals, and pharmacies should verify their stock and arrange return of unused product to their distributor.
The recalled product
- Product
- Granisetron HCl Injection, USP, 1 mg/mL, packaged in a) 1mL and b) 4 mL vials, Rx Only, For Intravenous Use Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Injectable / Antiemetic
- Hazard
- cgmp-deviation
- incomplete-stability-testing
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27